

## Programme

09.10 – 09.40	Registration
09.40 – 10.20	An update to suspected or known interstitial lung disease in the elderly. Dr Ludmila Shulgina
10.20 – 11.00	Rheumatology – A practice update. Dr Vivek Rajagopal
11.00	COFFEE
11.20 – 12.00	To Dialyze or Not To Dialyze. Dr Vivian Yiu
12.00 – 13.00	Trainee presentations
13.00 – 14.00	LUNCH
14.00 – 14.40	The use of immunotherapy in cancer. Dr Dan Patterson
14.40 – 15.30	Regional BGS Business Meeting
15.30	COFFEE & CLOSE

**The British Geriatrics Society acknowledges with grateful thanks, the support given through sponsorship from:**

**Daiichi Sanyko and Pfizer**

CPD Accreditation: This meeting has applied for 4 CPD credits

Speakers Biographies –



**@GeriSoc #BGS Conf**

**Dr Ludmilla Shulgina**

Dr Shulgina is a Respiratory Physician at West Suffolk Hospital. She completed an MD at University of East Anglia.

**Dr Vivek Rajagopal**

Dr Vivek Rajagopal is a Consultant Rheumatologist and Acute Physician at West Suffolk Hospital. He trained at the Wessex Deanery and was appointed at West Suffolk Hospital in 2008. He is currently the clinical Director for Acute and Emergency care at West Suffolk Hospital. Interested in vasculitis and connective tissue disease.

**Dr Vivian Yiu**

Dr Vivian Yiu is a Consultant Nephrologist and Physician at the West Suffolk Hospital. She trained at the University of Cambridge and in the East of England. She developed the Nephrology service at West Suffolk Hospital in conjunction with Dr Petchey which now encompasses general nephrology, pre dialysis, transplant, diabetes/renal clinics as well as a dialysis unit. She also has a keen interest in education and is currently a tutor for the Cambridge Graduate Course in medicine (and Fellow at Lucy Cavendish College) as well as an educational/clinical supervisor.

**Dr Dan Patterson**

Consultant Medical Oncologist appointed at West Suffolk Hospital in 2011 specialising in thoracic and gastrointestinal malignancies, cancer of unknown primary and acute oncology. I have developed a particular interest in the use of cancer immunotherapy and how to manage their toxicities.

